In the last 5 years, many studies highlighted NRF2 as a potential therapeutic target to treat neurodegenerative diseases (Lastres-Becker et al. 2016; Skibinski et al. 2017; Deshmukh et al. 2017; Dinkova-Kostova et al. 2018; Petrillo et al. 2020; Brandes and Gray 2020). Here, NFE2L2 is linked to neurodegenerative disease.